This disclosure is directed to: (a) processes for preparing intermediates useful for the preparation of a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; and (c) pharmaceutical compositions comprising the intermediates or salts.